Olema Pharmaceuticals, Inc.

Informe acción NasdaqGS:OLMA

Capitalización de mercado: US$628.7m

Salud financiera de hoja de balance de Olema Pharmaceuticals

Salud financiera controles de criterios 6/6

Olema Pharmaceuticals tiene un patrimonio de los accionistas total de $253.9M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $276.9M y $23.1M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$261.81m
PatrimonioUS$253.90m
Total pasivoUS$23.05m
Activos totalesUS$276.95m

Actualizaciones recientes sobre salud financiera

Recent updates

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Mar 28

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04
Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Jun 11
We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Mar 01
Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Olema Oncology grants stock options for 58.3K shares

Oct 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 13
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Aug 09

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Jul 21

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

May 29
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 08
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Our Take On Olema Pharmaceuticals

Jan 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 19
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Jun 04
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 19
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($266.5M) de OLMA superan a sus pasivos a corto plazo ($21.6M).

Pasivo a largo plazo: Los activos a corto plazo de OLMA ($266.5M) superan a sus pasivos a largo plazo ($1.4M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: OLMA está libre de deudas.

Reducción de la deuda: OLMA no ha tenido ninguna deuda en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: OLMA tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: OLMA dispone de suficiente cash runway para 2.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 41.5% cada año.


Descubre empresas con salud financiera